Oncternal Therapeutics, Inc. (GTU.F)

0.0000 -6.5200 (-100.00%) As of 09:00AM CEST. Market open.

Oncternal Therapeutics, Inc.

12230 El Camino Real
Suite 230
San Diego, CA 92130
United States
858 434 1113
https://www.oncternal.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 27

Key executives

Name	Title	Pay	Exercised	Year born
Dr. James B. Breitmeyer M.D., Ph.D.	President, CEO & Director	761.18k	N/A	1954
Dr. Salim Yazji M.D.	Chief Medical Officer	513.14k	N/A	1969
Mr. Richard G. Vincent CPA	CFO & Treasurer	490.04k	N/A	1964
Dr. Rajesh Krishnan Ph.D.	Chief Technical & Scientific Officer	N/A	N/A	1974
Mr. Chase C. Leavitt	General Counsel & Secretary	N/A	N/A	1982
Mr. Pablo Urbaneja	Senior Vice President of Corporate Development	N/A	N/A	N/A
Anita Wiseth	Senior Vice President of Human Resources	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Corporate governance

Oncternal Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.